FDA Approved: JYNARQUE — Supplemental Application (Otsuka America Pharmaceutical, Inc.)

View source ↗

Summary

FDA approved a supplemental application for JYNARQUE (tolvaptan) by Otsuka America Pharmaceutical, expanding labeling to cover a new indication for autosomal do…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autosomal Dominant Polycystic Kidney Disease

Drugs mentioned

• JYNARQUE (tolvaptan)

Snippet

SUPPL AP for JYNARQUE (TOLVAPTAN)